Pan African Clinical Trials Registry
South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0835 or +27 21 938 0967
Email: pactradmin@mrc.ac.za Website: pactr.samrc.ac.za
Trial no.: PACTR202509813688898 Date of Registration: 17/09/2025
Trial Status: Registered in accordance with WHO and ICMJE standards
TRIAL DESCRIPTION
Public title Restoring Life and Health Through Continuity Genome Restorer (CGR): A New Breakthrough for Africa and the World
Official scientific title Continuity Genome Restorer (CGR): Restoring the Resonance of Life in Multi-Disease Conditions
Brief summary describing the background and objectives of the trial Background Despite decades of progress in global medicine, Africa and the world continue to face high burdens of chronic and terminal illnesses — including diabetes, blood disorders, kidney failure, HIV/AIDS, bone infections, neurodegenerative conditions, and psychosis. Conventional medicine remains limited to chemical drugs, invasive surgeries, or lifelong organ transplantation, which often prolong suffering without restoring true health. The Human Genome Project provided a genetic map but did not solve the underlying challenge of restoring life when DNA resonance is broken. To address this gap, the Continuity Genome Restorer (CGR) has been developed. CGR is a non-invasive, resonance-based technology built on the Fourth Law of Logic (Continuity), designed to restore genomic resonance and enable natural regeneration of blood, tissues, bones, organs, and neural circuits. Summary The CGR-AFRICA Trial is a multi-country, multi-disease pilot clinical study aimed at evaluating the safety and effectiveness of CGR in reversing chronic and life-threatening conditions. The trial will enroll 5,000 participants across 11 African countries, with each participant receiving three CGR sessions over six months, followed by 18 months of monthly monitoring. Primary outcomes include genomic continuity restoration (via resonance mapping), blood regeneration, wound/bone healing, organ function recovery, and disease reversal in diabetes, HIV/AIDS, and kidney failure. Secondary outcomes include improvements in quality of life, avoidance of amputations/transplants, telomere lengthening (aging reversal), and immune system restoration. This will be Africa’s first large-scale trial in Continuity Medicine, positioning the continent as the global leader in resonance-based healthcare innovation.
Type of trial Non-Randomised
Acronym (If the trial has an acronym then please provide) CGR-AFRICA, Continuity Genome Restorer – African Framework for Resonance-Based Innovative Clinical
Disease(s) or condition(s) being studied Anaesthesia,Cancer,Cardiology,Circulatory System,Digestive System,Ear, Nose and Throat,Eye Diseases,Genetic Diseases,Haematological Disorders,Infections and Infestations,Injury, Occupational Diseases, Poisoning,Kidney Disease,Mental and Behavioural Disorders,Musculoskeletal Diseases,Neonatal Diseases,Nervous System Diseases,Nutritional, Metabolic, Endocrine,Obstetrics and Gynecology,Oral Health,Orthopaedics,Paediatrics,Pregnancy and Childbirth,Respiratory,Skin and Connective Tissue Diseases,Urological and Genital Diseases
Sub-Disease(s) or condition(s) being studied Ebola,Fertility-female,Fertility-male,HIV/AIDS,Malaria,Tuberculosis
Purpose of the trial Treatment: Devices
Anticipated trial start date 01/01/2026
Actual trial start date 17/04/2026
Anticipated date of last follow up 31/12/2027
Actual Last follow-up date 31/12/2027
Anticipated target sample size (number of participants) 5000
Actual target sample size (number of participants) 5000
Recruitment status Not yet recruiting
Publication URL Under Development
Secondary Ids Issuing authority/Trial register
STUDY DESIGN
Intervention assignment Allocation to intervention If randomised, describe how the allocation sequence was generated Describe how the allocation sequence/code was concealed from the person allocating the participants to the intervention arms Masking If masking / blinding was used
Single Group Non-randomised Allocation Sequence/Code was not concealed Open-label(Masking Not Used)
INTERVENTIONS
Intervention type Intervention name Dose Duration Intervention description Group size Nature of control
Experimental Group Continuity Genome Restorer The Continuity Genome Restorer (CGR) will be delivered as a non-invasive resonance-based intervention in designated clinical centers. Delivery Method: Participants will undergo continuity resonance mapping using CGR technology to identify genomic discontinuities. Resonance restoration will then be applied through calibrated biofield resonance emitters that realign the DNA’s natural continuity field. No drugs, injections, or surgical procedures will be administered. Environment: Sessions conducted in a controlled clinical setting, overseen by trained CGR-certified clinical staff. Each session lasts approximately 60–90 minutes, followed by observation and patient feedback recording. Safety: As a non-invasive, non-chemical technology, CGR avoids the risks of toxicity, drug side effects, or surgical complications. Patients are monitored monthly for biomarkers of genomic restoration, wound closure, organ function, and quality of life outcomes. Each participant will be involved in the trial for 24 months total. Core Intervention Period: 6 months (3 CGR sessions: baseline, 3 months, 6 months). Extended Follow-Up: 18 months of monthly resonance monitoring and clinical assessments. Total trial duration for all participants: 2 years (January 2026 – December 2027). The Continuity Genome Restorer (CGR) 🧬✨ is a non-invasive resonance-based technology designed to restore the continuity field of the human genome, enabling natural regeneration of blood, tissues, bones, and organs without the use of drugs, surgery, or organ transplantation. How it Works: Participants undergo continuity resonance mapping at baseline to identify genomic discontinuities associated with disease. CGR then applies calibrated biofield resonance emitters to realign and restore the DNA’s natural resonance field. This restoration reactivates the body’s innate ability to regenerate blood, close chronic wounds, rebuild bone tissue, reverse organ failure, and reduce chronic pain. Sessions: Session 1 (Baseline): Mapping + initial CGR restoration. Session 2 (3 months): Recalibration and monitoring. Session 3 (6 months): Final resonance reinforcement and mapping comparison. Follow-Up: Monthly resonance monitoring for up to 24 months total. Environment: Conducted in clinical trial centers equipped with CGR devices. Supervised by trained CGR-certified clinicians. Each session lasts 60–90 minutes and involves no chemical, surgical, or invasive procedure. Expected Outcomes: Restoration of genomic continuity signatures. Reversal of conditions such as blood disorders, diabetes, kidney failure, chronic wound infections, and bone degeneration. Long-term improvements in quality of life, mobility, and organ function. 5000
ELIGIBILITY CRITERIA
List inclusion criteria List exclusion criteria Age Category Minimum age Maximum age Gender
Participants must meet all of the following: Age: 13–80 years old. Residence: Must reside in one of the participating African countries during the trial period. Diagnosis: Clinically diagnosed with at least one of the following conditions: Blood disorders (e.g., sickle cell disease, anemia, rare bone marrow failure). Diabetes (Type 1 or Type 2). Chronic kidney disease or history of kidney failure. Chronic wound infections (non-healing wounds, risk of amputation). Bone infections or degeneration (osteomyelitis, fracture non-healing, arthritis-related degeneration). HIV/AIDS with ongoing immune compromise despite treatment. Organ failure (early-to-moderate stage heart, liver, or lung dysfunction). Neurodegenerative diseases (early-stage Parkinson’s, Alzheimer’s, multiple sclerosis). Autoimmune conditions (e.g., lupus, rheumatoid arthritis). Psychosis or severe psychiatric disorders not responding to conventional therapy. Disease Stage: Must have conditions considered non-responsive or poorly responsive to conventional treatments, or where invasive/life-threatening interventions (amputation, transplant, lifelong drug dependency) are being considered. Consent/Assent: Adults (≥18 years): Able and willing to provide written informed consent. Adolescents (13–17 years): Able to provide assent, with parental/guardian consent required. Commitment: Willing to attend all CGR sessions and follow-up visits for the full 24-month trial duration. Participants will not be eligible if they meet any of the following: Age: Younger than 13 years or older than 80 years. Pregnancy and Breastfeeding: Pregnant or breastfeeding women. Pregnant adolescents (13–17 years) are excluded due to unknown resonance effects on fetal/infant development. Guardian Refusal: Adolescents (13–17 years) whose parent/guardian does not provide written consent. Active Cancer: Currently undergoing chemotherapy, radiotherapy, or other aggressive cancer treatments. Severe Psychiatric Illness: Individuals with uncontrolled psychiatric or cognitive conditions (e.g., schizophrenia with acute crisis, severe dementia) that impair ability to consent/assent or comply with study requirements. Substance Abuse: Active alcohol or substance abuse likely to interfere with adherence. Medical Instability: Patients with advanced, unstable, or end-stage organ failure (e.g., requiring mechanical ventilation, dialysis dependence without residual function, end-stage liver failure). Concurrent Experimental Therapy: Participation in another interventional clinical trial within the last 6 months. Non-Adherence Risk: Inability or unwillingness to attend the 3 core CGR sessions and monthly follow-ups for 24 months. Contraindication to Resonance Monitoring: Presence of implanted electronic medical devices (e.g., certain pacemakers, defibrillators) that could interfere with resonance mapping. 80 and over: 80+ Year,Adolescent: 13 Year(s)-17 Year(s),Adult: 18 Year(s)-44 Year(s),Aged: 65 Year(s)-79 Year(s),Middle Aged: 45 Year(s)-64 Year(s) 13 Year(s) 80 Year(s) Both
ETHICS APPROVAL
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 01/11/2025 University of Botswana Medical Research Centre
Ethics Committee Address
Street address City Postal code Country
School of Medicine P Bag 00713 Gaborone Botswana Gaborone 0000 Botswana
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 01/11/2025 National Health Research Centre
Ethics Committee Address
Street address City Postal code Country
New Referral Hospital Bots Abelo Lepereng Maseri 0000 Lesotho
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 01/11/2025 Mbabane Government Hospital Health Research Unit
Ethics Committee Address
Street address City Postal code Country
Mbabane Eswatini Mbabane 0000 Swaziland
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 01/11/2025 Chris Hani Baragwanath Academic Hospital
Ethics Committee Address
Street address City Postal code Country
Old Potchefstroom Road, Soweto, South Africa Johannesburg 1864 South Africa
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 01/11/2025 Kenyatta National Hospital
Ethics Committee Address
Street address City Postal code Country
Hospital Rd Nairobi Kenya Nairobi 0000 Kenya
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 01/11/2025 Lagos University Teaching Hospital
Ethics Committee Address
Street address City Postal code Country
Idi-Araba, Surulere, Lagos State, Nigeria Lagos 0000 Nigeria
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 01/11/2025 Cairo University Medical Research Centre
Ethics Committee Address
Street address City Postal code Country
Al-Saray Street El Manial Cairo 11956 Egypt Cairo 0000 Egypt
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 01/11/2025 Mulago National Referral Hospital
Ethics Committee Address
Street address City Postal code Country
Haji Musa Kasule Road Kampala Uganda Kampala 0000 Uganda
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 01/11/2025 Windhoek Central Hospital
Ethics Committee Address
Street address City Postal code Country
Ooievaar Street,Windhoek Namibia Windhoek North, Namibia Windhoek 0000 Namibia
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 01/11/2025 Korle Bu Teaching Hospital Accra
Ethics Committee Address
Street address City Postal code Country
Guggisberg Ave Accra Ghana Accra 0000 Ghana
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 01/11/2025 King Faisal Hospital Kigali
Ethics Committee Address
Street address City Postal code Country
KG 544 Street 10 Kacyiru Gasabo Kigali Kigali 0000 Rwanda
OUTCOMES
Type of outcome Outcome Timepoint(s) at which outcome measured
Primary Outcome Primary Outcomes ✅ Restoration of genomic continuity resonance as measured by continuity resonance mapping (baseline vs post-intervention). Clinical disease reversal indicators, including: Blood regeneration (hemoglobin, white cell, platelet counts). Kidney/liver function markers (creatinine, ALT/AST). Wound closure rates and bone healing (radiological and clinical). Glucose regulation (HbA1c for diabetes). T0, T2, T3, T5, T7
Secondary Outcome Quality of life improvements (mobility, pain reduction, energy levels, sleep). Prevention of invasive interventions (avoidance of amputations, transplants, or lifelong drug escalation). Telomere length restoration and markers of aging reversal. Immune system regeneration in HIV/AIDS and chronic infections. Patient-reported outcomes (emotional well-being, ability to work, daily functioning). Long-term durability of CGR effects (12–24 months follow-up). T0, T1, T2, T3, T4, T5, T6, T7
RECRUITMENT CENTRES
Name of recruitment centre Street address City Postal code Country
Princess Marina Hospital and University of Botswana Medical Research Centre Princess Marina Hospital Administrative Building 2nd Floor Gaborone Botswana Gaborone 0000 Botswana
Queen Mamohato Memorial Hospital and National Health Research Centre New Referral Hospital Bots Abelo Lepereng Maseru 0000 Lesotho
Mbabane Government Hospital Health Research Unit Mbabane Eswatini Mbabane 0000 Swaziland
Chris Hani Baragwanath Academic Hospital Old Potchefstroom Road, Soweto, South Africa Johannesburg 1861 South Africa
Kenyatta National Hospital and University of Nairobi Medical School Hospital Rd Nairobi Kenya Nairobi 0000 Kenya
Lagos University Teaching Hospital Ishaga Rd Idi-Araba Lagos 102215 Lagos Nigeria Lagos 0000 Nigeria
Cairo University Medical Research Centre Al-Saray Street El Manial Cairo 11956 Egypt Cairo 0000 Egypt
Mulago National Referral Hospital and Makerere University College of Health Sciences Haji Musa Kasule Road Kampala Uganda Kampala 0000 Uganda
King Faisal Hospital Kigali KG 544 Street 10 Kacyiru Gasabo Kigali Kigali 0000 Rwanda
Windhoek Central Hospital C3WC GF3 Windhoek Namibia Windhoek 0000 Namibia
Korle Bu Teaching Hospital Accra Guggisberg Ave Accra Ghana Accra 0000 Ghana
FUNDING SOURCES
Name of source Street address City Postal code Country
SCVX Validator Economy Plot No 11683 End of Block 5 Gaborone Botswana Gaborone 0000 Botswana
SPONSORS
Sponsor level Name Street address City Postal code Country Nature of sponsor
Primary Sponsor SCVX Validator Economy Plot No 11683 End of Block 5 Gaborone Botswana Gaborone 0000 Botswana The trial is fully funded by SCVX Validator Economy through Social Capital Hours SCH instruments and supported by QUSD SCH bridge mechanisms. Additional institutional and in-kind support will be provided by recruitment centres and national health ministries across participating African countries
COLLABORATORS
Name Street address City Postal code Country
CONTACT PEOPLE
Role Name Email Phone Street address
Principal Investigator Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Plot No 11683 End of Block 5 Gaborone Botswana
City Postal code Country Position/Affiliation
Gaborone 0000 Botswana Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Plot No 11683 End of Block 5 Gaborone Botswana
City Postal code Country Position/Affiliation
Gaborone 0000 Botswana Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Plot No 11683 End of Block 5 Gaborone Botswana
City Postal code Country Position/Affiliation
Gaborone 0000 Botswana Principal Investigator
Role Name Email Phone Street address
Principal Investigator Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 New Referral Hospital Bots Abelo Lepereng
City Postal code Country Position/Affiliation
Maseru 0000 Lesotho Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 New Referral Hospital Bots Abelo Lepereng
City Postal code Country Position/Affiliation
Maseru 0000 Lesotho Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 New Referral Hospital Bots Abelo Lepereng
City Postal code Country Position/Affiliation
Maseru 0000 Lesotho Principal Investigator
Role Name Email Phone Street address
Principal Investigator Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Old Potchefstroom Road, Soweto, South Africa
City Postal code Country Position/Affiliation
Johannesburg 0000 South Africa Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Old Potchefstroom Road, Soweto, South Africa
City Postal code Country Position/Affiliation
Johannesburg 0000 South Africa Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Old Potchefstroom Road, Soweto, South Africa
City Postal code Country Position/Affiliation
Johannesburg 0000 South Africa Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Mbabane Eswatini
City Postal code Country Position/Affiliation
Mbabane 0000 Swaziland Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Mbabane Eswatini
City Postal code Country Position/Affiliation
Mbabane 0000 Swaziland Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Mbabane Eswatini
City Postal code Country Position/Affiliation
Mbabane 0000 Swaziland Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Hospital Rd Nairobi Kenya
City Postal code Country Position/Affiliation
Nairobi 0000 Kenya Principal Investigator
Role Name Email Phone Street address
Principal Investigator Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Hospital Rd Nairobi Kenya
City Postal code Country Position/Affiliation
Nairobi 0000 Kenya Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Hospital Rd Nairobi Kenya
City Postal code Country Position/Affiliation
Nairobi 0000 Kenya Principal Investigator
Role Name Email Phone Street address
Principal Investigator Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Ishaga Rd Idi-Araba Lagos 102215 Lagos Nigeria
City Postal code Country Position/Affiliation
Lagos 0000 Nigeria Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Ishaga Rd Idi-Araba Lagos 102215 Lagos Nigeria
City Postal code Country Position/Affiliation
Lagos 0000 Nigeria Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Ishaga Rd Idi-Araba Lagos 102215 Lagos Nigeria
City Postal code Country Position/Affiliation
Lagos 0000 Nigeria Principal Investigator
Role Name Email Phone Street address
Principal Investigator Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Al-Saray Street El Manial Cairo 11956 Egypt
City Postal code Country Position/Affiliation
Cairo 0000 Egypt Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Al-Saray Street El Manial Cairo 11956 Egypt
City Postal code Country Position/Affiliation
Cairo 0000 Egypt Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Al-Saray Street El Manial Cairo 11956 Egypt
City Postal code Country Position/Affiliation
Cairo 0000 Egypt Principal Investigator
Role Name Email Phone Street address
Principal Investigator Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Haji Musa Kasule Road Kampala Uganda
City Postal code Country Position/Affiliation
Kampala 0000 Uganda Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Haji Musa Kasule Road Kampala Uganda
City Postal code Country Position/Affiliation
Kampala 0000 Uganda Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Haji Musa Kasule Road Kampala Uganda
City Postal code Country Position/Affiliation
Kampala 0000 Uganda Principal Investigator
Role Name Email Phone Street address
Principal Investigator Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 KG 544 Street 10 Kacyiru Gasabo Kigali
City Postal code Country Position/Affiliation
Kigali 0000 Rwanda Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 KG 544 Street 10 Kacyiru Gasabo Kigali
City Postal code Country Position/Affiliation
Kigali 0000 Rwanda Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 KG 544 Street 10 Kacyiru Gasabo Kigali
City Postal code Country Position/Affiliation
Kigali 0000 Rwanda Principal Investigator
Role Name Email Phone Street address
Principal Investigator Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 C3WC GF3 Windhoek Namibia
City Postal code Country Position/Affiliation
Windhoek 0000 Namibia Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 C3WC GF3 Windhoek Namibia
City Postal code Country Position/Affiliation
Windhoek 0000 Namibia Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 C3WC GF3 Windhoek Namibia
City Postal code Country Position/Affiliation
Windhoek 0000 Namibia Principal Investigator
Role Name Email Phone Street address
Principal Investigator Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Guggisberg Ave Accra Ghana
City Postal code Country Position/Affiliation
Accra 0000 Ghana Principal Investigator
Role Name Email Phone Street address
Public Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Guggisberg Ave Accra Ghana
City Postal code Country Position/Affiliation
Accra 0000 Ghana Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Ssemakula Luyima ceo@scvxafrica.co.site 26669532985 Guggisberg Ave Accra Ghana
City Postal code Country Position/Affiliation
Accra 0000 Ghana Principal Investigator
REPORTING
Share IPD Description Additional Document Types Sharing Time Frame Key Access Criteria
Yes IPD Description: De-identified individual participant data (IPD) will be collected during the trial, including: Baseline demographic data (age, sex, country, disease condition). Clinical laboratory results (blood counts, renal/liver function, glucose, HIV viral load where applicable). Continuity resonance mapping signatures (pre- and post-CGR). Imaging results (bone healing scans, wound photographs where ethically permissible). Patient-reported outcomes (pain scores, mobility, quality of life surveys). Safety and adverse event reports. All IPD will be anonymized prior to storage and sharing, with no personal identifiers linked to the dataset. Sharing Plan: Summary results will be made publicly available on the PACTR registry and SCVX website within 12 months of trial completion (by December 2028). Anonymized IPD datasets may be shared with accredited researchers upon request, subject to approval by the SCVX Data Access Committee and participating countries’ Ethics Committees. Data will be stored in a secure, access-controlled repository managed by SCVX in collaboration with the University of Botswana Medical Research Centre. Informed Consent Form,Statistical Analysis Plan,Study Protocol Summary results will be made publicly available on the PACTR registry and SCVX platforms within 12 months after trial completion (by December 2028). Anonymized IPD datasets will be available for qualified researchers starting 12 months post-trial completion and will remain accessible for a minimum of 10 years (2028–2038). Eligibility: Access to anonymized IPD will be granted to qualified researchers, institutions, or health agencies with a formal research proposal that aligns with the trial objectives (e.g., genomic medicine, resonance-based therapies, public health analysis). Approval Process: Requests must be submitted in writing to the SCVX Data Access Committee (DAC). Each request will be reviewed for scientific merit, ethical compliance, and alignment with participant consent. Data Use Agreement (DUA): Approved researchers must sign a DUA that: Prohibits re-identification of participants. Limits use of data to the approved research purpose. Requires acknowledgment of SCVX and CGR-AFRICA in publications. Ethics Oversight: Access will only be granted if the researcher provides evidence of approval (or waiver) from their own institutional ethics committee. Time Frame: Data available from 12 months post-study completion (Dec 2028) for a period of 10 years (until Dec 2038).
URL Results Available Results Summary Result Posting Date First Journal Publication Date
To be provided in due course No
Result Upload 1: Result Upload 2: Result Upload 3: Result Upload 4: Result Upload 5:
Result URL Hyperlinks Link To Protocol
Result URL Hyperlinks
Changes to trial information
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Trial description 11/09/2025 As requested per PACTR Response Primary Objective: To evaluate the effectiveness of Continuity Genome Restorer (CGR) in restoring genomic continuity resonance and reversing multi-system health failures, including blood disorders, bone infections, kidney failure, diabetes, and chronic wound healing. Secondary Objectives: To assess the safety and tolerability of CGR resonance restoration. To measure improvements in quality of life, reduction of chronic pain, and avoidance of invasive procedures (amputation, transplantation). To establish continuity resonance mapping as a clinical biomarker for disease reversal. Background Despite decades of progress in global medicine, Africa and the world continue to face high burdens of chronic and terminal illnesses — including diabetes, blood disorders, kidney failure, HIV/AIDS, bone infections, neurodegenerative conditions, and psychosis. Conventional medicine remains limited to chemical drugs, invasive surgeries, or lifelong organ transplantation, which often prolong suffering without restoring true health. The Human Genome Project provided a genetic map but did not solve the underlying challenge of restoring life when DNA resonance is broken. To address this gap, the Continuity Genome Restorer (CGR) has been developed. CGR is a non-invasive, resonance-based technology built on the Fourth Law of Logic (Continuity), designed to restore genomic resonance and enable natural regeneration of blood, tissues, bones, organs, and neural circuits. Summary The CGR-AFRICA Trial is a multi-country, multi-disease pilot clinical study aimed at evaluating the safety and effectiveness of CGR in reversing chronic and life-threatening conditions. The trial will enroll 5,000 participants across 11 African countries, with each participant receiving three CGR sessions over six months, followed by 18 months of monthly monitoring. Primary outcomes include genomic continuity restoration (via resonance mapping), blood regeneration, wound/bone healing, organ function recovery, and disease reversal in diabetes, HIV/AIDS, and kidney failure. Secondary outcomes include improvements in quality of life, avoidance of amputations/transplants, telomere lengthening (aging reversal), and immune system restoration. This will be Africa’s first large-scale trial in Continuity Medicine, positioning the continent as the global leader in resonance-based healthcare innovation.
Section Name Field Name Date Reason Old Value Updated Value
Eligibility Inclusion criteria 11/09/2025 The minimum age of eligibility has been lowered from 18 years to 13 years. Reason for Change: Disease Burden in Adolescents: Many of the target conditions — such as sickle cell disease, Type 1 diabetes, and HIV/AIDS — disproportionately affect adolescents in Africa, with onset often occurring between 13–17 years. Excluding this age group would deny early access to potentially life-saving intervention. Ethical Safeguards: Adolescents will only be enrolled with assent from the participant and written consent from a parent or legal guardian, in line with international ethical guidelines. Continuity Medicine Applicability: CGR is non-invasive and does not involve chemical drugs or surgery, making it safer for adolescents compared to high-risk pharmaceutical interventions. Pilot Inclusivity: Expanding eligibility ensures that the trial reflects the real health demographics of Africa, where a large portion of the population is under 18. Upper Age Limit Unchanged: Participants above 80 years remain excluded due to frailty, multiple comorbidities, and increased trial safety risks. Participants must meet all of the following: Age: 18–80 years old. Residence: Must reside in one of the participating African countries during the trial period. Diagnosis: Clinically diagnosed with at least one of the following conditions: Blood disorders (e.g., anemia, sickle cell disease, rare bone marrow failure). Diabetes (Type 1 or Type 2). Chronic kidney disease or history of kidney failure. Chronic wound infections (non-healing wounds, risk of amputation). Bone infections or degeneration (osteomyelitis, post-fracture non-healing, arthritis-related degeneration). HIV/AIDS with ongoing immune compromise despite antiretroviral therapy. Organ failure (early to moderate stage heart, liver, or lung dysfunction). Neurodegenerative diseases (e.g., early-stage Parkinson’s, Alzheimer’s, multiple sclerosis). Autoimmune conditions (e.g., lupus, rheumatoid arthritis). Disease Stage: Conditions considered non-responsive or poorly responsive to conventional treatments, or where invasive/life-threatening interventions (amputation, transplant, lifelong drug dependency) are being considered. Consent: Able and willing to provide written informed consent. Commitment: Willing to attend all CGR sessions and follow-up visits for the full 24-month trial. Participants must meet all of the following: Age: 13–80 years old. Residence: Must reside in one of the participating African countries during the trial period. Diagnosis: Clinically diagnosed with at least one of the following conditions: Blood disorders (e.g., sickle cell disease, anemia, rare bone marrow failure). Diabetes (Type 1 or Type 2). Chronic kidney disease or history of kidney failure. Chronic wound infections (non-healing wounds, risk of amputation). Bone infections or degeneration (osteomyelitis, fracture non-healing, arthritis-related degeneration). HIV/AIDS with ongoing immune compromise despite treatment. Organ failure (early-to-moderate stage heart, liver, or lung dysfunction). Neurodegenerative diseases (early-stage Parkinson’s, Alzheimer’s, multiple sclerosis). Autoimmune conditions (e.g., lupus, rheumatoid arthritis). Psychosis or severe psychiatric disorders not responding to conventional therapy. Disease Stage: Must have conditions considered non-responsive or poorly responsive to conventional treatments, or where invasive/life-threatening interventions (amputation, transplant, lifelong drug dependency) are being considered. Consent/Assent: Adults (≥18 years): Able and willing to provide written informed consent. Adolescents (13–17 years): Able to provide assent, with parental/guardian consent required. Commitment: Willing to attend all CGR sessions and follow-up visits for the full 24-month trial duration.
Section Name Field Name Date Reason Old Value Updated Value
Eligibility Exclusion criteria 11/09/2025 Exclusion Criteria – Reason for Change The exclusion criteria were updated to reflect the inclusion of adolescents (13–17 years), which required additional ethical and safety safeguards. Reason for Change: Adolescent Participation: Since adolescents (13–17 years) are now eligible, exclusions were added for: Guardian refusal (when a parent/legal guardian does not provide consent). Pregnant adolescents (to avoid risks to unborn or breastfeeding infants). Enhanced Ethical Safeguards: The criteria were adjusted to ensure full protection of minors, aligning with international clinical trial standards. Risk Management: By clarifying exclusions (guardian refusal, pregnancy in adolescents, device interference), the study minimizes risks while safely expanding eligibility to younger participants. Consistency with Inclusion Change: The shift from 18+ only to 13–80 years necessitated parallel updates in exclusion to ensure that vulnerable adolescents are not exposed to risks without safeguards. Participants will not be eligible if they meet any of the following: Age: Below 18 years or above 80 years. Pregnancy and Breastfeeding: Pregnant or breastfeeding women (due to unknown resonance effects on fetal/infant development). Active Cancer: Currently undergoing chemotherapy, radiotherapy, or other aggressive cancer treatments. Severe Psychiatric Illness: Individuals with uncontrolled psychiatric or cognitive conditions (e.g., schizophrenia, severe dementia) that impair the ability to consent or comply with study requirements. Substance Abuse: Active alcohol or substance abuse likely to interfere with adherence. Medical Instability: Patients with advanced, unstable, or end-stage organ failure (e.g., requiring mechanical ventilation, dialysis dependence without residual function, end-stage liver failure). Concurrent Experimental Therapy: Participation in another interventional clinical trial within the last 6 months. Non-Adherence Risk: Inability or unwillingness to attend the 3 core CGR sessions and monthly follow-ups for 24 months. Contraindication to Resonance Monitoring: Any implanted electronic medical devices (e.g., certain pacemakers, defibrillators) that could interfere with resonance mapping. Participants will not be eligible if they meet any of the following: Age: Younger than 13 years or older than 80 years. Pregnancy and Breastfeeding: Pregnant or breastfeeding women. Pregnant adolescents (13–17 years) are excluded due to unknown resonance effects on fetal/infant development. Guardian Refusal: Adolescents (13–17 years) whose parent/guardian does not provide written consent. Active Cancer: Currently undergoing chemotherapy, radiotherapy, or other aggressive cancer treatments. Severe Psychiatric Illness: Individuals with uncontrolled psychiatric or cognitive conditions (e.g., schizophrenia with acute crisis, severe dementia) that impair ability to consent/assent or comply with study requirements. Substance Abuse: Active alcohol or substance abuse likely to interfere with adherence. Medical Instability: Patients with advanced, unstable, or end-stage organ failure (e.g., requiring mechanical ventilation, dialysis dependence without residual function, end-stage liver failure). Concurrent Experimental Therapy: Participation in another interventional clinical trial within the last 6 months. Non-Adherence Risk: Inability or unwillingness to attend the 3 core CGR sessions and monthly follow-ups for 24 months. Contraindication to Resonance Monitoring: Presence of implanted electronic medical devices (e.g., certain pacemakers, defibrillators) that could interfere with resonance mapping.
Section Name Field Name Date Reason Old Value Updated Value
Eligibility Age group 11/09/2025 The eligible age group was changed from 18–80 years to 13–80 years. Reason for Change: Disease Burden in Adolescents: Many of the target diseases for CGR — such as sickle cell disease, Type 1 diabetes, and HIV/AIDS — often begin in adolescence. Excluding 13–17 year-olds would deny them access to a potentially life-saving intervention. Ethical Balance: Adolescents (13–17 years) can now be safely included with dual safeguards: their own assent and written guardian/parental consent. Non-Invasive Nature of CGR: Since CGR is non-chemical and non-surgical, it poses minimal risk compared to conventional drug or surgical trials, making it suitable for adolescents. African Demographics: Africa has a very young population, and including adolescents ensures the trial reflects the continent’s real health needs. Upper Limit (80+): Remains unchanged — participants above 80 are excluded due to frailty and comorbidities that may confound results. Adult: 19 Year-44 Year, Middle Aged: 45 Year(s)-64 Year(s), Aged: 65+ Year(s), 80 and over: 80+ Year Adolescent: 13 Year-18 Year, Adult: 19 Year-44 Year, Middle Aged: 45 Year(s)-64 Year(s), Aged: 65+ Year(s), 80 and over: 80+ Year
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 11/09/2025 Required for submission FALSE, National Health Research Centre, New Referral Hospital Bots Abelo Lepereng, Maseri, 0000, Lesotho, 01 Nov 2025, , +26622220000, qmmhHRrecruitment@gmail.com,
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 11/09/2025 Required for submission FALSE, Mbabane Government Hospital Health Research Unit, Mbabane Eswatini, Mbabane, 0000, Swaziland, 01 Nov 2025, , +26824042113, secretary@ehls.org.sz,
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 11/09/2025 Required for submission FALSE, Chris Hani Baragwanath Academic Hospital, Old Potchefstroom Road, Soweto, South Africa, Johannesburg, 1864, South Africa, 01 Nov 2025, , 00270119330967, Nita.Soma@gauteng.gov.za,
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 11/09/2025 Required for submission FALSE, Kenyatta National Hospital , Hospital Rd Nairobi Kenya, Nairobi, 0000, Kenya, 01 Nov 2025, , +254202726300, knhadmin@knh.or.ke,
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 11/09/2025 Required for submission FALSE, Lagos University Teaching Hospital, Idi-Araba, Surulere, Lagos State, Nigeria, Lagos, 0000, Nigeria, 01 Nov 2025, , +2348070591395, enquiry@lasuth.org.ng,
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 11/09/2025 Required for submission FALSE, Cairo University Medical Research Centre, Al-Saray Street El Manial Cairo 11956 Egypt, Cairo, 0000, Egypt, 01 Nov 2025, , +2025729584, kasralainyrec@kasralainy.edu.eg,
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 11/09/2025 Required for submission FALSE, Mulago National Referral Hospital , Haji Musa Kasule Road Kampala Uganda, Kampala, 0000, Uganda, 01 Nov 2025, , +256414554008, admin@mulagohospital.go.ug,
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 11/09/2025 Required for submission FALSE, Windhoek Central Hospital, Ooievaar Street,Windhoek Namibia Windhoek North, Namibia, Windhoek , 0000, Namibia, 01 Nov 2025, , +264612039111, enquiry@wch.gov.na,
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 11/09/2025 Required for submission FALSE, Korle Bu Teaching Hospital Accra, Guggisberg Ave Accra Ghana, Accra, 0000, Ghana, 01 Nov 2025, , +233302739510, dma.sec@kbth.gov.gh,
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 11/09/2025 Required for submission FALSE, King Faisal Hospital Kigali, KG 544 Street 10 Kacyiru Gasabo Kigali, Kigali, 0000, Rwanda, 01 Nov 2025, , +250788123200, info@kfhkigali.com,
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Ishaga Rd Idi-Araba Lagos 102215 Lagos Nigeria, Lagos, 0000, Nigeria, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Gaborone , Gaborone , Botswana, Principal Investigator Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Gaborone , 0000, Botswana, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Gaborone, Gaborone, Botswana, Principal Investigator Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Gaborone, 0000, Botswana, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Gaborone, Gaborone, Botswana, Principal Investigator Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Gaborone, 0000, Botswana, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Gaborone, 0000, Lesotho, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Gaborone, 0000, Lesotho, Principal Investigator Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Maseru, 0000, Lesotho, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Maseru, 0000, Lesotho, Principal Investigator Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, New Referral Hospital Bots Abelo Lepereng, Maseru, 0000, Lesotho, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Maseru, 0000, Lesotho, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Maseru, 0000, Lesotho, Principal Investigator Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, New Referral Hospital Bots Abelo Lepereng, Maseru, 0000, Lesotho, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Maseru, 0000, Lesotho, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Maseru, 0000, Lesotho, Principal Investigator Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, New Referral Hospital Bots Abelo Lepereng, Maseru, 0000, Lesotho, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Johannesburg, 0000, South Africa, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Johannesburg, 0000, South Africa, Principal Investigator Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Old Potchefstroom Road, Soweto, South Africa, Johannesburg, 0000, South Africa, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Johannesburg, 0000, South Africa, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Plot No 11683 End of Block 5 Gaborone Botswana, Johannesburg, 0000, South Africa, Principal Investigator Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Old Potchefstroom Road, Soweto, South Africa, Johannesburg, 0000, South Africa, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Old Potchefstroom Road, Soweto, South Africa, Johannesburg, 0000, South Africa, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Ishaga Rd Idi-Araba Lagos 102215 Lagos Nigeria, Lagos, 0000, Nigeria, Principal Investigator Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Hospital Rd Nairobi Kenya, Nairobi, 0000, Kenya, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Hospital Rd Nairobi Kenya, Nairobi, 0000, Kenya, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Mbabane Eswatini, Mbabane, 0000, Swaziland, Principal Investigator Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Hospital Rd Nairobi Kenya, Nairobi, 0000, Kenya, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Ishaga Rd Idi-Araba Lagos 102215 Lagos Nigeria, Lagos, 0000, Nigeria, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Ishaga Rd Idi-Araba Lagos 102215 Lagos Nigeria, Lagos, 0000, Nigeria, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Ishaga Rd Idi-Araba Lagos 102215 Lagos Nigeria, Lagos, 0000, Nigeria, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Al-Saray Street El Manial Cairo 11956 Egypt, Cairo, 0000, Egypt, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Al-Saray Street El Manial Cairo 11956 Egypt, Cairo, , Egypt, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Al-Saray Street El Manial Cairo 11956 Egypt, Cairo, , Egypt, Principal Investigator Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Al-Saray Street El Manial Cairo 11956 Egypt, Cairo, 0000, Egypt, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Al-Saray Street El Manial Cairo 11956 Egypt, Cairo, 0000, Egypt, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Haji Musa Kasule Road Kampala Uganda, Kampala, 0000, Uganda, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Haji Musa Kasule Road Kampala Uganda, Kampala, 0000, Uganda, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Haji Musa Kasule Road Kampala Uganda, Kampala, 0000, Uganda, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, KG 544 Street 10 Kacyiru Gasabo Kigali, Kigali, 0000, Rwanda, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, KG 544 Street 10 Kacyiru Gasabo Kigali, Kigali, 0000, Rwanda, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, KG 544 Street 10 Kacyiru Gasabo Kigali, Kigali, 0000, Rwanda, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, C3WC GF3 Windhoek Namibia, Windhoek, 0000, Namibia, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, C3WC GF3 Windhoek Namibia, Windhoek, 0000, Namibia, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, C3WC GF3 Windhoek Namibia, Windhoek, 0000, Namibia, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Principal Investigator, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Guggisberg Ave Accra Ghana, Accra, 0000, Ghana, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Public Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Guggisberg Ave Accra Ghana, Accra, 0000, Ghana, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Contact People Contacs List 11/09/2025 Submission required Scientific Enquiries, Ssemakula, Luyima, Mr., ceo@scvxafrica.co.site, , 26669532985, Guggisberg Ave Accra Ghana, Accra, 0000, Ghana, Principal Investigator
Section Name Field Name Date Reason Old Value Updated Value
Eligibility Minimum age 11/09/2025 The eligible age group was changed from 18–80 years to 13–80 years. Reason for Change: Disease Burden in Adolescents: Many of the target diseases for CGR — such as sickle cell disease, Type 1 diabetes, and HIV/AIDS — often begin in adolescence. Excluding 13–17 year-olds would deny them access to a potentially life-saving intervention. Ethical Balance: Adolescents (13–17 years) can now be safely included with dual safeguards: their own assent and written guardian/parental consent. Non-Invasive Nature of CGR: Since CGR is non-chemical and non-surgical, it poses minimal risk compared to conventional drug or surgical trials, making it suitable for adolescents. African Demographics: Africa has a very young population, and including adolescents ensures the trial reflects the continent’s real health needs. Upper Limit (80+): Remains unchanged — participants above 80 are excluded due to frailty and comorbidities that may confound results. 18 Year(s) 13 Year(s)